Please enable JavaScript to continue using this application.

Compare $AVTX vs $GYRE | Chartloom

Compare

$AVTX vs $GYRE

Avalo Therapeutics Inc · Gyre Therapeutics Inc

AVTX

Avalo Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Compare $AVTX vs $GYRE

Comparing Avalo Therapeutics Inc and Gyre Therapeutics Inc

AVTXAvalo Therapeutics Inc

GYREGyre Therapeutics Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

GYRE

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

AVTX$722M

GYRE$643M

Enterprise Value

AVTX$639M

GYRE$600M

Price

AVTX$13.65

GYRE$7.04

P/E Ratio

AVTXN/A

GYREN/A

P/S Ratio

AVTX12,238.73x

GYRE5.39x

EV/Sales

AVTX10,825.47x

GYRE5.03x

EV/EBITDA

AVTX0.00x

GYRE286.88x

P/B Ratio

AVTX1.79x

GYRE5.78x

P/FCF Ratio

AVTXN/A

GYREN/A

EV/FCF

AVTX-9.35x

GYRE-35.74x

PEG Ratio

AVTXN/A

GYREN/A

Forward P/E (NTM)

AVTXN/A

GYREN/A

Forward P/S (NTM)

AVTXN/A

GYREN/A

Revenue (TTM)

AVTX$59K

GYRE$119M

Revenue Growth (YoY)

AVTX-86.6%

GYRE16.8%

Forward Rev Growth

AVTX1345.1%

GYRE21.1%

Gross Margin (TTM)

AVTX242.2%

GYRE94.3%

Operating Margin (TTM)

AVTX0.0%

GYRE0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

GYRE-8.5%

Net Margin (TTM)

AVTX-170055.9%

GYRE-15.5%

FCF Margin (TTM)

AVTX-115745.8%

GYRE-14.1%

Net Income (TTM)

AVTX$-100M

GYRE$-18M

FCF (TTM)

AVTX$-68M

GYRE$-17M

EPS (TTM)

AVTX-$2.30

GYRE-$0.18

ROE (TTM)

AVTX-5803.0%

GYRE-1584.0%

ROA (TTM)

AVTX-4822.0%

GYRE-1014.0%

ROIC (TTM)

AVTX-5729.0%

GYRE-1584.0%

Cash

AVTX$85M

GYRE$43M

Debt

AVTX$2M

GYRE$0

Net Cash/Debt

AVTX$83M

GYRE$43M

Current Ratio (TTM)

AVTX19.31x

GYRE4.26x

Quick Ratio (TTM)

AVTX18.95x

GYRE3.64x

Debt/Equity (TTM)

AVTX0.00x

GYRE0.00x

Debt/Assets (TTM)

AVTX0.0%

GYRE0.0%

Interest Coverage (TTM)

AVTXN/A

GYREN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

GYRE0.00x

Beta

AVTX0.62

GYRE2.46

52W Performance

AVTX-4.0%

GYRE-3.6%

YTD Performance

AVTX-19.8%

GYRE3.4%

% from 52W High

AVTX-43.8%

GYRE-25.3%

% from 52W Low

AVTX9.1%

GYRE29.4%

Asset Turnover (TTM)

AVTX0.00x

GYRE0.70x

FCF Yield (TTM)

AVTX-9.5%

GYRE-2.6%

Earnings Yield (TTM)

AVTX-13.9%

GYRE-2.9%

Dividend Yield (TTM)

AVTXN/A

GYREN/A

Rule of 40

AVTX-115,832.4

GYRE2.8

EV/GP/RG

AVTX1.31

GYRE0.23

Ticker research

View AVTX research View GYRE research

Metric	AVTX Avalo Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$722M	$643M
Enterprise Value	$639M	$600M
Price	$13.65	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	5.39x
EV/Sales	10,825.47x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	1.79x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$119M
Revenue Growth (YoY)	-86.6%	16.8%
Forward Rev Growth	1345.1%	21.1%
Profitability
Gross Margin (TTM)	242.2%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-8.5%
Net Margin (TTM)	-170055.9%	-15.5%
FCF Margin (TTM)	-115745.8%	-14.1%
Net Income (TTM)	$-100M	$-18M
FCF (TTM)	$-68M	$-17M
EPS (TTM)	-$2.30	-$0.18
ROE (TTM)	-5803.0%	-1584.0%
ROA (TTM)	-4822.0%	-1014.0%
ROIC (TTM)	-5729.0%	-1584.0%
Financial Health
Cash	$85M	$43M
Debt	$2M	$0
Net Cash/Debt	$83M	$43M
Current Ratio (TTM)	19.31x	4.26x
Quick Ratio (TTM)	18.95x	3.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.46
52W Performance	-4.0%	-3.6%
YTD Performance	-19.8%	3.4%
% from 52W High	-43.8%	-25.3%
% from 52W Low	9.1%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-9.5%	-2.6%
Earnings Yield (TTM)	-13.9%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	2.8
EV/GP/RG	1.31	0.23
Ticker research	View AVTX research	View GYRE research

Valuation

P/S Ratio

GYRE

5.39x

AVTX

12,238.73x

EV/FCF

GYRE

-35.74x

AVTX

-9.35x

Growth & revenue

Revenue Growth TTM

GYRE

16.8%

AVTX

-86.6%

Forward Revenue Growth

AVTX

1345.1%

GYRE

21.1%

Profitability & performance

Gross Margin

AVTX

242.2%

GYRE

94.3%

ROE

GYRE

-1584.0%

AVTX

-5803.0%

FCF Yield %

GYRE

-2.6%

AVTX

-9.5%

52-Week Performance

GYRE

-3.6%

AVTX

-4.0%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

AVTX$722M

GYRE$643M

Enterprise Value

AVTX$639M

GYRE$600M

Price

AVTX$13.65

GYRE$7.04

P/E Ratio

AVTXN/A

GYREN/A

P/S Ratio

AVTX12,238.73x

GYRE5.39x

EV/Sales

AVTX10,825.47x

GYRE5.03x

EV/EBITDA

AVTX0.00x

GYRE286.88x

P/B Ratio

AVTX1.79x

GYRE5.78x

P/FCF Ratio

AVTXN/A

GYREN/A

EV/FCF

AVTX-9.35x

GYRE-35.74x

PEG Ratio

AVTXN/A

GYREN/A

Forward P/E (NTM)

AVTXN/A

GYREN/A

Forward P/S (NTM)

AVTXN/A

GYREN/A

Revenue (TTM)

AVTX$59K

GYRE$119M

Revenue Growth (YoY)

AVTX-86.6%

GYRE16.8%

Forward Rev Growth

AVTX1345.1%

GYRE21.1%

Gross Margin (TTM)

AVTX242.2%

GYRE94.3%

Operating Margin (TTM)

AVTX0.0%

GYRE0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

GYRE-8.5%

Net Margin (TTM)

AVTX-170055.9%

GYRE-15.5%

FCF Margin (TTM)

AVTX-115745.8%

GYRE-14.1%

Net Income (TTM)

AVTX$-100M

GYRE$-18M

FCF (TTM)

AVTX$-68M

GYRE$-17M

EPS (TTM)

AVTX-$2.30

GYRE-$0.18

ROE (TTM)

AVTX-5803.0%

GYRE-1584.0%

ROA (TTM)

AVTX-4822.0%

GYRE-1014.0%

ROIC (TTM)

AVTX-5729.0%

GYRE-1584.0%

Cash

AVTX$85M

GYRE$43M

Debt

AVTX$2M

GYRE$0

Net Cash/Debt

AVTX$83M

GYRE$43M

Current Ratio (TTM)

AVTX19.31x

GYRE4.26x

Quick Ratio (TTM)

AVTX18.95x

GYRE3.64x

Debt/Equity (TTM)

AVTX0.00x

GYRE0.00x

Debt/Assets (TTM)

AVTX0.0%

GYRE0.0%

Interest Coverage (TTM)

AVTXN/A

GYREN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

GYRE0.00x

Beta

AVTX0.62

GYRE2.46

52W Performance

AVTX-4.0%

GYRE-3.6%

YTD Performance

AVTX-19.8%

GYRE3.4%

% from 52W High

AVTX-43.8%

GYRE-25.3%

% from 52W Low

AVTX9.1%

GYRE29.4%

Asset Turnover (TTM)

AVTX0.00x

GYRE0.70x

FCF Yield (TTM)

AVTX-9.5%

GYRE-2.6%

Earnings Yield (TTM)

AVTX-13.9%

GYRE-2.9%

Dividend Yield (TTM)

AVTXN/A

GYREN/A

Rule of 40

AVTX-115,832.4

GYRE2.8

EV/GP/RG

AVTX1.31

GYRE0.23

Ticker research

View AVTX research View GYRE research

Metric	AVTX Avalo Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$722M	$643M
Enterprise Value	$639M	$600M
Price	$13.65	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	5.39x
EV/Sales	10,825.47x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	1.79x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$119M
Revenue Growth (YoY)	-86.6%	16.8%
Forward Rev Growth	1345.1%	21.1%
Profitability
Gross Margin (TTM)	242.2%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-8.5%
Net Margin (TTM)	-170055.9%	-15.5%
FCF Margin (TTM)	-115745.8%	-14.1%
Net Income (TTM)	$-100M	$-18M
FCF (TTM)	$-68M	$-17M
EPS (TTM)	-$2.30	-$0.18
ROE (TTM)	-5803.0%	-1584.0%
ROA (TTM)	-4822.0%	-1014.0%
ROIC (TTM)	-5729.0%	-1584.0%
Financial Health
Cash	$85M	$43M
Debt	$2M	$0
Net Cash/Debt	$83M	$43M
Current Ratio (TTM)	19.31x	4.26x
Quick Ratio (TTM)	18.95x	3.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.46
52W Performance	-4.0%	-3.6%
YTD Performance	-19.8%	3.4%
% from 52W High	-43.8%	-25.3%
% from 52W Low	9.1%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-9.5%	-2.6%
Earnings Yield (TTM)	-13.9%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	2.8
EV/GP/RG	1.31	0.23
Ticker research	View AVTX research	View GYRE research